Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer

Dan Zandberg, MD
Published: Friday, Oct 13, 2017



Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.

Overall the HAWK trial shows promising results, states Zandburg, and physicians are anxiously awaiting results from the ongoing phase III trial.



Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.

Overall the HAWK trial shows promising results, states Zandburg, and physicians are anxiously awaiting results from the ongoing phase III trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Publication Bottom Border
Border Publication
x